Single photon tomography in Alzheimer's disease and the dementias*

https://doi.org/10.1016/S0001-2998(05)80238-7Get rights and content

Measurements of brain blood flow has evolved over the past 50 years, and during the latter half of that time radionuclide techniques have been used to study this important function. Using Xenon 133 and scintillation multiprobe systems, several teams of investigators measured regional cerebral blood flow (rCBF), and noted that under many circumstances it could be equated with local brain physiological activity. The dementias were investigated using the scintillation multiprobe method, and posterior flow deficits were described in patients who were thought to have Alzheimer's disease. The multiprobe technique gave way first to planar, and then tomographic imaging, with initial favorable results achieved by positron emission tomography (PET). Soon investigators learned to measure rCBF with single-photon emission computed tomography (SPECT) using highsensitivity systems and 133Xe as a tracer, or highresolution systems with 123I-iodoamphetamine (IMP), and later, 99mTc-HMPAO. Three-dimensional tomographic imaging shows to advantage the flow patterns that characterize Alzheimer's disease, with rCBF reductions in temporal, parietal, and sometimes frontal areas, as opposed to randomly distributed deficits in multiinfarct dementia, reduced frontal flow in entities such as Pick's disease, and others. Herein we will review our own experience with high-sensitivity rCBF SPECT in 119 patients with dementia, and with high-resolution SPECT, using a new, three-camera scanner and 99mTc-HMPAO in an additional 39 patients. SPECT rCBF study of patients with dementia and Alzheimer's disease, will aid in separating patients with untreatable Alzheimer's from those patients who may have treatable causes of dementia, and will be useful in evaluating experimental drugs for the treatment of Alzheimer's disease.

References (42)

  • FrackowiakRSJ et al.

    A prospective study of regional cerebral blood flow and oxygen utilization in dementia using positron emission tomography and oxygen-15

    J Cereb Blood Flow Metab

    (1981)
  • AlaviA et al.

    Determination of cerebral metabolism in senile dementia using F-18 deoxyglucose and positron emission tomography

    J Nucl Med

    (1980)
  • MetterEJ et al.

    Cerebral metabolic relationships for selected brain regions in Alzheimer's, Huntington's and Parkinson's diseases

    J Cereb Blood Flow Metab

    (1981)
  • BensonDF et al.

    The fluorodeoxyglucose F-18 scan in Alzheimer's and multi-infarct dementia

    Arch Neurol

    (1983)
  • FosterNL et al.

    Alzheimer's disease: Focal cortical changes shown by positron emission tomography

    Neurology

    (1983)
  • DuaraR et al.

    Positron emission tomography in Alzheimer's disease

    Neurology

    (1986)
  • CohenMB et al.

    Differential diagnosis of dementia with “pure” I-123 iodoamphetamine and a clinical camera

    J Nucl Med

    (1983)
  • WinchellHS et al.

    Development of I-123-labeled amines for brain studies: Localization of I-123 iodophenylalkyl amines in rat brain

    J Nucl Med

    (1980)
  • SharpP et al.

    Application of Iodine-123-labeled isopropylamphetamine imaging to the study of dementia

    J Nucl Med

    (1986)
  • JagustWJ et al.

    The diagnosis of dementia with single photon emission computed tomography

    Arch Neurol

    (1987)
  • JohnsonKA et al.

    Cerebral perfusion imaging in Alzheimer's disease: use of single photon emission computed tomography and iofetamine hydrochloride I-123

    Arch Neurol

    (1987)
  • Cited by (0)

    *

    Supported in part by grants from the Southwestern Medical Foundation and the Amon Carter Foundation, and by Grant No. AG08013 from the National Institutes of Health.

    View full text